Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Review and a Single Center Experience
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare pulmonary condition, characterized by diffuse proliferation of neuroendocrine cells in the respiratory epithelium. DIPNECH lesions are less than 5 mm in size and are limited to the basement membrane with no invasion. There is limited information regarding epidemiology, natural history of disease progression, or the management of this rare entity. We present the experience of a center with extensive expertise in neuroendocrine disease.
A cohort of patients (N = 13) with DIPNECH treated and followed at our institution was identified. We describe the our approach to their care, our disease management and also provide a review of DIPNECH pathophysiology.
Our patient cohort consisted of twelve females and one male with a mean age of 63 years at the time of diagnosis. Dyspnea on exertion and dry cough were the most common presenting symptoms. Two patients were under surveillance without treatment; three patients were treated with a short-acting somatostatin analog; three patients were treated with azithromycin alone; four were treated with a combination of long-acting monthly somatostatin analogs and azithromycin; one patient received a combination of long-acting somatostatin analog and everolimus. Five patients had concomitant bronchial carcinoids.
DIPNECH is a rare pathology that can profoundly affect a patient’s quality of life. Paroxysmal coughing episodes can be difficult to treat. Our limited single center experience shows encouraging response to use of somatostatin analogs, azithromycin, and everolimus in the management of debilitating DIPNECH associated symptoms.
KeywordsDIPNECH Octreotide Azithromycin Everolimus
The authors thank Catherine Anthony, Ph.D. for assistance with manuscript preparation.
Conception and design: All authors; Administrative support: LA; Provision of materials: All authors; Collection and assembly of data: ZM and AC; Data interpretation: ZM; Manuscript writing and final approval: All authors.
Compliance with Ethical Standards
Conflict of interest
No author has any conflict of interest to declare.
- 4.Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (2015) Tumors of the lung. In: Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG (eds) WHO classification of tumors of the lung, pleural, thumus and heart, vol 7, 4th edn. International Agency for Reseach on Cancer, Lyon, pp 73–79Google Scholar
- 7.Hospital and University Center of Coimbra (2015) http://www.chuc.min-saude.pt. Accessed Jan 2018
- 10.Travis WD (2010) Advances in neuroendocrine lung tumors. Ann Oncol 21(Suppl 7):765–771Google Scholar
- 13.Feyrter F (1938) Uber diffuse endocrine epitheliale organe. J. A. Bath, LeipzigGoogle Scholar
- 21.Mourad MR, Hamblin MJ (2015) Sirolimus for the treatment of diffuse idiopathic pulmonary neuroendocrine cell Hyperplasia (DIPNECH). A38. Tell me what you see: atypical presentations of ild. Am Thorac Soc 2015:A1501–A1501Google Scholar